|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2020. CA Cancer J Clin. 70:7–30. 2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Leong AS and Raymond WA: Prognostic
parameters in breast cancer. Pathology. 21:169–175. 1989.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Taneja P, Maglic D, Kai F, Zhu S, Kendig
RD, Fry EA and Inoue K: Classical and novel prognostic markers for
breast cancer and their clinical significance. Clin Med Insights
Oncol. 4:15–34. 2010.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Soliman NA and Yussif SM: Ki-67 as a
prognostic marker according to breast cancer molecular subtype.
Cancer Biol Med. 13:496–504. 2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Cao SS and Lu CT: Recent perspectives of
breast cancer prognosis and predictive factors. Oncol Lett.
12:3674–3678. 2016.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Giuliano AE, Hunt KK, Ballman KV, Beitsch
PD, Whitworth PW, Blumencranz PW, Leitch AM, Saha S, McCall LM and
Morrow M: Axillary dissection vs no axillary dissection in women
with invasive breast cancer and sentinel node metastasis: A
randomized clinical trial. JAMA. 305:569–575. 2011.PubMed/NCBI View Article : Google Scholar
|
|
7
|
McVeigh TP, Hughes LM, Miller N, Sheehan
M, Keane M, Sweeney KJ and Kerin MJ: The impact of Oncotype DX
testing on breast cancer management and chemotherapy prescribing
patterns in a tertiary referral centre. Eur J Cancer. 50:2763–2770.
2014.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Naoi Y and Noguchi S: Multi-gene
classifiers for prediction of recurrence in breast cancer patients.
Breast Cancer. 23:12–18. 2016.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Hornberger J, Cosler LE and Lyman GH:
Economic analysis of targeting chemotherapy using a 21-gene RT-PCR
assay in lymph-node-negative, estrogen-receptor-positive,
early-stage breast cancer. Am J Manag Care. 11:313–324.
2005.PubMed/NCBI
|
|
10
|
Cobleigh MA, Tabesh B, Bitterman P, Baker
J, Cronin M, Liu ML, Borchik R, Mosquera JM, Walker MG and Shak S:
Tumor gene expression and prognosis in breast cancer patients with
10 or more positive lymph nodes. Clin Cancer Res. 11:8623–8631.
2005.PubMed/NCBI View Article : Google Scholar
|
|
11
|
van 't Veer LJ, Dai H, van de Vijver MJ,
He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ,
Witteveen AT, et al: Gene expression profiling predicts clinical
outcome of breast cancer. Nature. 415:530–536. 2002.PubMed/NCBI View
Article : Google Scholar
|
|
12
|
Davis RE and Williams M: Mitochondrial
function and dysfunction: An update. J Pharmacol Exp Ther.
342:598–607. 2012.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Hsu CC, Tseng LM and Lee HC: Role of
mitochondrial dysfunction in cancer progression. Exp Biol Med
(Maywood). 241:1281–1295. 2016.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Boland ML, Chourasia AH and Macleod KF:
Mitochondrial dysfunction in cancer. Front Oncol.
3(292)2013.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Porporato PE, Filigheddu N, Pedro JMB,
Kroemer G and Galluzzi L: Mitochondrial metabolism and cancer. Cell
Res. 28:265–280. 2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Grasso D, Zampieri LX, Capeloa T, Van de
Velde JA and Sonveaux P: Mitochondria in cancer. Cell Stress.
4:114–146. 2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Abu-Amero KK, Alzahrani AS, Zou M and Shi
Y: High frequency of somatic mitochondrial DNA mutations in human
thyroid carcinomas and complex I respiratory defect in thyroid
cancer cell lines. Oncogene. 24:1455–1460. 2005.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Warowicka A, Kwasniewska A and
Gozdzicka-Jozefiak A: Alterations in mtDNA: A qualitative and
quantitative study associated with cervical cancer development.
Gynecol Oncol. 129:193–198. 2013.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Gao JY, Song BR, Peng JJ and Lu YM:
Correlation between mitochondrial TRAP-1 expression and lymph node
metastasis in colorectal cancer. World J Gastroenterol.
18:5965–5971. 2012.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Qian XL, Li YQ, Gu F, Liu FF, Li WD, Zhang
XM and Fu L: Overexpression of ubiquitous mitochondrial creatine
kinase (uMtCK) accelerates tumor growth by inhibiting apoptosis of
breast cancer cells and is associated with a poor prognosis in
breast cancer patients. Biochem Biophys Res Commun. 427:60–66.
2012.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Sotgia F and Lisanti MP: Mitochondrial
markers predict survival and progression in non-small cell lung
cancer (NSCLC) patients: Use as companion diagnostics. Oncotarget.
8:68095–68107. 2017.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Ambrosini-Spaltro A, Salvi F, Betts CM,
Frezza GP, Piemontese A, Del Prete P, Baldoni C, Foschini MP and
Viale G: Oncocytic modifications in rectal adenocarcinomas after
radio and chemotherapy. Virchows Arch. 448:442–448. 2006.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Wang Y, He S, Zhu X, Qiao W and Zhang J:
High copy number of mitochondrial DNA predicts poor prognosis in
patients with advanced stage colon cancer. Int J Biol Markers.
31:e382–e388. 2016.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Grupp K, Jedrzejewska K, Tsourlakis MC,
Koop C, Wilczak W, Adam M, Quaas A, Sauter G, Simon R, Izbicki JR,
et al: High mitochondria content is associated with prostate cancer
disease progression. Mol Cancer. 12(145)2013.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Sotgia F and Lisanti MP: Mitochondrial
biomarkers predict tumor progression and poor overall survival in
gastric cancers: Companion diagnostics for personalized medicine.
Oncotarget. 8:67117–67128. 2017.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Hu B and Guo Y: Inhibition of
mitochondrial translation as a therapeutic strategy for human
ovarian cancer to overcome chemoresistance. Biochem Biophys Res
Commun. 509:373–378. 2019.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Zhang Y, Qu Y, Gao K, Yang Q, Shi B, Hou P
and Ji M: High copy number of mitochondrial DNA (mtDNA) predicts
good prognosis in glioma patients. Am J Cancer Res. 5:1207–1216.
2015.PubMed/NCBI
|
|
28
|
Ragazzi M, de Biase D, Betts CM, Farnedi
A, Ramadan SS, Tallini G, Reis-Filho JS and Eusebi V: Oncocytic
carcinoma of the breast: Frequency, morphology and follow-up. Hum
Pathol. 42:166–175. 2011.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Williams SL, Valnot I, Rustin P and
Taanman JW: Cytochrome c oxidase subassemblies in fibroblast
cultures from patients carrying mutations in COX10, SCO1, or SURF1.
J Biol Chem. 279:7462–7469. 2004.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Ruiz C, Seibt S, Al Kuraya K, Siraj AK,
Mirlacher M, Schraml P, Maurer R, Spichtin H, Torhorst J, Popovska
S, et al: Tissue microarrays for comparing molecular features with
proliferation activity in breast cancer. Int J Cancer.
118:2190–2194. 2006.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Mirlacher M and Simon R: Recipient block
TMA technique. Methods Mol Biol. 664:37–44. 2010.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Al-Kuraya K, Schraml P, Torhorst J, Tapia
C, Zaharieva B, Novotny H, Spichtin H, Maurer R, Mirlacher M,
Köchli O, et al: Prognostic relevance of gene amplifications and
coamplifications in breast cancer. Cancer Res. 64:8534–8540.
2004.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Lebok P, Roming M, Kluth M, Koop C, Özden
C, Taskin B, Hussein K, Lebeau A, Witzel I, Wölber L, et al: p16
overexpression and 9p21 deletion are linked to unfavorable tumor
phenotype in breast cancer. Oncotarget. 7:81322–81331.
2016.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Lebok P, Mittenzwei A, Kluth M, Özden C,
Taskin B, Hussein K, Möller K, Hartmann A, Lebeau A, Witzel I, et
al: 8p deletion is strongly linked to poor prognosis in breast
cancer. Cancer Biol Ther. 16:1080–1087. 2015.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Yan M, Schwaederle M, Arguello D, Millis
SZ, Gatalica Z and Kurzrock R: HER2 expression status in diverse
cancers: Review of results from 37,992 patients. Cancer Metastasis
Rev. 34:157–164. 2015.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Lebok P, Kopperschmidt V, Kluth M,
Hube-Magg C, Özden C, B T, Hussein K, Mittenzwei A, Lebeau A,
Witzel I, et al: Partial PTEN deletion is linked to poor prognosis
in breast cancer. BMC Cancer. 15:963–910. 2015.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Simon R, Mirlacher M and Sauter G:
Immunohistochemical analysis of tissue microarrays. Methods Mol
Biol. 664:113–126. 2010.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Nieminen AI, Partanen JI, Hau A and
Klefstrom J: c-Myc primed mitochondria determine cellular
sensitivity to TRAIL-induced apoptosis. EMBO J. 26:1055–1067.
2007.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Desbiens KM, Deschesnes RG, Labrie MM,
Desfossés Y, Lambert H, Landry J and Bellmann K: c-Myc potentiates
the mitochondrial pathway of apoptosis by acting upstream of
apoptosis signal-regulating kinase 1 (Ask1) in the p38 signalling
cascade. Biochem J. 372:631–641. 2003.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Klefstrom J, Verschuren E and Evan G:
c-Myc augments the apoptotic activity of cytosolic death receptor
signaling proteins by engaging the mitochondrial apoptotic pathway.
J Biol Chem. 277:43224–43232. 2002.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Dang CV, O'Donnell KA, Zeller KI, Nguyen
T, Osthus RC and Li F: The c-Myc target gene network. Semin Cancer
Biol. 16:253–264. 2006.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Amati B, Frank SR, Donjerkovic D and
Taubert S: Function of the c-Myc oncoprotein in chromatin
remodeling and transcription. Biochim Biophys Acta. 1471:M135–M145.
2001.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Dang CV, Resar LM, Emison E, Kim S, Li Q,
Prescott JE, Wonsey D and Zeller K: Function of the c-Myc oncogenic
transcription factor. Exp Cell Res. 253:63–77. 1999.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Wonsey DR, Zeller KI and Dang CV: The
c-Myc target gene PRDX3 is required for mitochondrial homeostasis
and neoplastic transformation. Proc Natl Acad Sci USA.
99:6649–6654. 2002.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Li F, Wang Y, Zeller KI, Potter JJ, Wonsey
DR, O'Donnell KA, Kim JW, Yustein JT, Lee LA and Dang CV: Myc
stimulates nuclearly encoded mitochondrial genes and mitochondrial
biogenesis. Mol Cell Biol. 25:6225–6234. 2005.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Graves JA, Wang Y, Sims-Lucas S, Cherok E,
Rothermund K, Branca MF, Elster J, Beer-Stolz D, Van Houten B,
Vockley J and Prochownik EV: Mitochondrial structure, function and
dynamics are temporally controlled by c-Myc. PLoS One.
7(e37699)2012.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Miller DM, Thomas SD, Islam A, Muench D
and Sedoris K: c-Myc and cancer metabolism. Clin Cancer Res.
18:5546–5553. 2012.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Leites EP and Morais VA: Mitochondrial
quality control pathways: PINK1 acts as a gatekeeper. Biochem
Biophys Res Commun. 500:45–50. 2018.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Panigrahi DP, Praharaj PP, Bhol CS,
Mahapatra KK, Patra S, Behera BP, Mishra SR and Bhutia SK: The
emerging, multifaceted role of mitophagy in cancer and cancer
therapeutics. Semin Cancer Biol. 66:45–58. 2020.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Wang H, Ni HM, Chao X, Ma X, Rodriguez YA,
Chavan H, Wang S, Krishnamurthy P, Dobrowsky R, Xu DX, et al:
Double deletion of PINK1 and Parkin impairs hepatic mitophagy and
exacerbates acetaminophen-induced liver injury in mice. Redox Biol.
22(101148)2019.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Rak M, Bénit P, Chrétien D, Bouchereau J,
Schiff M, El-Khoury R, Tzagoloff A and Rustin P: Mitochondrial
cytochrome c oxidase deficiency. Clin Sci (Lond).
130:393–407. 2016.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Gundamaraju R, Lu W and Manikam R:
Revisiting Mitochondria Scored Cancer Progression and Metastasis.
Cancers (Basel). 13(432)2021.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Vieira AF and Schmitt F: An update on
breast cancer multigene prognostic tests-emergent clinical
biomarkers. Front Med (Lausanne). 5(248)2018.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Gogvadze V, Orrenius S and Zhivotovsky B:
Mitochondria as targets for cancer chemotherapy. Semin Cancer Biol.
19:57–66. 2009.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Leber B, Geng F, Kale J and Andrews DW:
Drugs targeting Bcl-2 family members as an emerging strategy in
cancer. Expert Rev Mol Med. 12(e28)2010.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Indran IR, Tufo G, Pervaiz S and Brenner
C: Recent advances in apoptosis, mitochondria and drug resistance
in cancer cells. Biochim Biophys Acta. 1807:735–745.
2011.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Dijk SN, Protasoni M, Elpidorou M, Kroon
AM and Taanman JW: Mitochondria as target to inhibit proliferation
and induce apoptosis of cancer cells: The effects of doxycycline
and gemcitabine. Sci Rep. 10(4363)2020.PubMed/NCBI View Article : Google Scholar
|
